Question 1

What does Pharmalliance Consulting Ltd specialize in?

Accepted Answer

Pharmalliance Consulting Ltd specializes in contamination control, GMP compliance, and quality risk management for regulated life science industries. We support pharmaceutical, biotechnology, and advanced therapy manufacturers in achieving regulatory compliance with EU Annex 1, FDA, EMA, and Health Canada standards.

Question 2

How can Pharmalliance help pharmaceutical companies meet EU Annex 1 requirements?

Accepted Answer

Pharmalliance provides expert guidance on implementing EU GMP Annex 1 (2022) through gap assessments, CCS creation, environmental monitoring strategies, and personnel training. We ensure your sterile manufacturing operations align with regulatory expectations for contamination control and sterility assurance.

Question 3

What is a Contamination Control Strategy (CCS) and why is it critical in GMP environments?

Accepted Answer

A Contamination Control Strategy (CCS) is a documented plan that integrates all control measures to prevent microbial, particulate, and endotoxin contamination. Required by EU Annex 1, a robust CCS protects product quality and patient safety in pharmaceutical manufacturing.

Question 4

Does Pharmalliance offer support for FDA or EMA inspection readiness?

Accepted Answer

Yes, Pharmalliance offers inspection readiness services for FDA, EMA, and Health Canada audits. We prepare your facility through mock audits, document reviews, and training, ensuring compliance with GMP, ICH Q9, and Annex 1 contamination control expectations.

Question 5

Which industries benefit most from Pharmalliance's contamination control expertise?

Accepted Answer

We support sterile pharmaceutical manufacturing, ATMPs, cell and gene therapy, medical devices, biologics, and compounding pharmacies. Our contamination control strategies are tailored for high-risk GMP environments where sterility, pyrogen control, and regulatory compliance are critical.

Question 6

Why is environmental monitoring critical to aseptic processing compliance?

Accepted Answer

Environmental monitoring (EM) provides real-time feedback on contamination control in cleanrooms. Pharmalliance ensures EM programs align with Annex 1, including continuous monitoring in Grade A zones, trend analysis, and actionable microbial limits to support sterility assurance.

Question 7

How often should we review and update our CCS document for GMP compliance?

Accepted Answer

EU Annex 1 mandates periodic review and updates of your CCS. Pharmalliance recommends annual reviews, or after any facility, process, or regulatory change. Regular updates ensure continuous improvement and alignment with evolving GMP expectations.

Question 8

Can Pharmalliance help us design a Quality Risk Management (QRM) program aligned with ICH Q9 (R1)?

Accepted Answer

Yes, our consultants specialize in building QRM programs aligned with ICH Q9 (R1). We help you apply risk tools like FMEA and HACCP to assess microbial, particulate, and cross-contamination risks in sterile manufacturing.

Question 9

How does Pharmalliance support gap assessments against EU Annex 1 contamination control requirements?

Accepted Answer

Pharmalliance performs detailed gap assessments comparing your current practices to Annex 1 (2022) and PDA TR90 requirements. We identify missing CCS elements, define remediation plans, and support implementation.

Question 10

What role does Pharmalliance play in contamination root cause investigations and CAPA development?

Accepted Answer

We provide expert root cause analysis and CAPA support for microbial, endotoxin, or particulate contamination events. Our structured approach integrates with your QMS to strengthen your contamination control lifecycle.

FREQUENTLY ASKED QUESTIONS

What does Pharmalliance Consulting Ltd specialise in?

Which industries benefit most from Pharmalliance's contamination control expertise?

Does Pharmalliance offer support for FDA or EMA inspection readiness?

How can Pharmalliance help pharmaceutical companies meet EU Annex 1 requirements?

What is a Contamination Control Strategy (CCS) and why is it critical in GMP environments?

How do I develop a robust Contamination Control Strategy (CCS) for sterile manufacturing?

What are the key elements of a contamination control program according to EU Annex 1?

How does Pharmalliance support gap assessments against EU Annex 1 contamination control requirements?

Why is environmental monitoring critical to aseptic processing compliance?

What is the difference between viable and non-viable contamination in GMP environments?

How can Pharmalliance assist in facility design reviews to prevent microbial contamination?

How often should we review and update our CCS document for GMP compliance?

What are the benefits of implementing a holistic CCS as per PDA TR90 guidance?

How do you measure the effectiveness of a contamination control strategy over time?

Can Pharmalliance help us design a Quality Risk Management (QRM) program aligned with ICH Q9 (R1)?

What role does Pharmalliance play in contamination root cause investigations and CAPA development?

How can I access Pharmalliance’s contamination control training modules?

Do you offer on-site or virtual GMP training for manufacturing personnel?